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Omega-3 fatty acids (FAs) have the potential to regulate gene expression via the peroxisome proliferator-activated receptor α
(PPARα); therefore, genetic variations in this gene may impact its transcriptional activity on target genes. It is hypothesized that
the transcriptional activity by wild-type L162-PPARα is enhanced to a greater extent than the mutated variant (V162-PPARα)i n
the presence of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or a mixture of EPA:DHA. To examine the functional
diﬀerence of the two allelic variants on receptor activity, transient co-transfections were performed in human hepatoma HepG2
cells activated with EPA, DHA and EPA:DHA mixtures. Results indicate that the addition of EPA or DHA demonstrate potential to
increasethetranscriptionalactivitybyPPARαwithrespecttobasallevelinbothvariants.Yet,theEPA:DHAmixturesenhancedthe
transcriptional activity to a greater extent than individual FAs indicating possible additive eﬀects of EPA and DHA. Additionally,
the V162 allelic form of PPARα demonstrated consistently lower transcriptional activation when incubated with EPA, DHA or
EPA:DHA mixtures than, the wild-type variant. In conclusion, both allelic variants of the PPARα L162V are activated by omega-3
FAs; however, the V162 allelic form displays a lower transcriptional activity than the wild-type variant.
Copyright © 2009 Iwona Rudkowska et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Higher intake of long-chain n-3 fatty acids (FAs) eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA) has
been recommended to decrease plasma triglyceride (TG)
levels. Conventionally, the mechanism of action after n-3
FAs intake focused on plasma membrane ﬂuidity; however,
recentlytheemphasisshiftedtoregulationofgeneexpression
[1]. In particular, FAs and their derivatives are physiolog-
ical ligands of peroxisome proliferator-activated receptor
α (PPARα). As such they activate the PPARα-retinoid X
receptor (RXR) heterodimer-dependent gene transcription
by binding to the peroxisome proliferator response elements
(PPRE) in the promoter region of target genes [2]. Target
genesincludelipoproteinlipase(LPL)involvedinplasmaTG
clearance [2].
Several polymorphisms within the PPARα gene and the
encoded proteins have been identiﬁed including L162V and
V227A, which are the most common PPARα polymorphisms
reported [3]. Of particular interest, the PPARα L162V
polymorphism has been associated with obesity indices and
plasma lipid levels in numerous studies [4–8]. Additionally,
Robitaille et al. in 2004 found that the interaction between
the PPARα L162V polymorphism and fat intake estimated
from a food frequency questionnaire (FFQ) explains a
signiﬁcant percentage of the variance observed in waist girth
in a sample of 260 French-Canadians [9]. Tai et al. in 2005
[10] also established that the eﬀect of the PPARα L162V
polymorphism on plasma TG and apolipoprotein (apo)-CIII
concentrations depends on the dietary polyunsaturated FA
(PUFA), with a high intake triggering lower TG in carriers of
the V162-PPARα variant. Finally, Paradis et al. in 2002 [11]2 PPAR Research
demonstrated that the interindividual variations in total
cholesterol, apo A-I, and cholesterol concentrations in
small low-density lipoprotein (LDL) particles observed after
modiﬁcation of the polyunsaturated/saturated FA ratio of
the diet is partly attributable to the PPARα L162V poly-
morphism. Clearly, both epidemiological and interventional
studies demonstrate a relation between the PPARα L162V
polymorphisms, metabolic parameters, and FAs intake; yet,
only two functional studies examined the receptor activity
of the L162V polymorphic variants activated with synthetic
agonists-ﬁbrates [4, 12]. It was demonstrated that the eﬀect
of the L162V polymorphic variants on the transcriptional
activationwasassociatedwiththeconcentrationoftheligand
to which it is exposed [12].
For that reason, the aim of this functional study was to
determine whether the transcriptional activity by the wild-
type variant, L162-PPARα, is enhanced in the presence of
natural PPARα agonists-omega-3 FAs, mimicking the action
of synthetic PPARα agonists, comparatively to the variant,
V162-PPARα.
2. LaboratoryMethods
2.1. Plasmid Construction. The wild-type L162-PPAR ex-
pression plasmid (pSG5-hPPARα vector) was a kind gift
from Pr. B. Staels (Unit´ e INSERM 545, Institut Pasteur de
Lille, France). The pSG5-mRXRα plasmid was described
previously [13]. The V162-PPARα expression plasmid was
derived from the wild-type, through site-directed mutage-
nesis (QuickChange site-directed mutagenesis kit, Strata-
gene, La Jolla, Calif, USA) using the 5 -CGATTTCAC-
AAGTGCGTTTCTGTCGGGATG-3  oligonucleotide (the
nucleotide in boldface type denotes the C→G change
mutated base). Variant cDNAs were directly sequenced to
conﬁrm that no spurious base changes have been introduced
during the procedure. As a response element representative
of the vast variety of human PPREs, we choose the consensus
artiﬁcialdirectrepeat(DR)1sequenceforanalyzingthefunc-
tional consequences of L162V variation on PPARα activation
by omega-3 FAs. Thus, a reporter plasmid (DR1x6-PPRE)
was generated by cloning in front of the thymidine kinase
promoter-driven luciferase reporter gene (TKpGL3 vector),
six copies of the 5 -AAAACTAGGTCAAAGGTCACGG-3 
sequence where underlined nucleotides correspond to the
direct repeat of the AGGTCA hexamer.
2.2. Transient Transfection and n-3 Fatty Acids Activation.
Human hepatoma HepG2 cells were cultured in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) supplemented by 10%
fetal bovine serum (FBS), 1% of streptomycin penicillin, 1%
of sodium pyruvate and 1% of glutamine. HepG2 cells were
plated at a density of 75 × 103 cells/well of 24-well plates
which were then transfected using the ExGen reagent (Invit-
rogen, Burlington, Canada) with 50ng of the DR1x6-PPRE
reporter plasmid, 10ng of the PPARα (wild-type or mutant)
and RXR expression plasmids and 30ng of the pRL-NULL
expression vector (Promega) for 6hours 37
◦C. All samples
were complemented with pBS-SK+ plasmid (Stratagene) to
an identical amount (500ng/well). Similar experiments were
performed with a negative control consisting of the empty
TK-pGL3-basic plasmid (Promega). After transfection, cells
were cultured in DMEM supplemented by 0.2% FBS for
24 hours to strengthen cell membrane before addition of
FAs. Afterwards, cells were transactivated for 24 hours in
absence or presence of omega-3 FAs in concentrations
varying between 1–15μM to reﬂect biological plasma or red
blood cells concentration of FAs [14]. Cells were treated
with either solvent (dimethyl sulfoxide (DMSO), 0.01% ﬁnal
concentration), or treatments of EPA and/or DHA (Sigma-
Aldrich, Oakville, ON, Canada). Brieﬂy, pure EPA or DHA
was dissolved by serial dilution to 1, 5, 10, and 15μMi n
DMSO. For mixtures of 5:5, 15:5, and 5:15μM EPA:DHA,
the dissolved individual omega-3 FAs at appropriate con-
centrations were mixed together. The luciferase activity was
quantiﬁed with a luminometer (Bertholus, LB956V) and
expressed as fold induction in the presence of variable doses
of omega-3 FAs over control. Ciproﬁbrate (250μM) (Sigma-
Aldrich) was used as a positive control of induction. The
assays were performed in triplicates. The experiment was
conducted in duplicate.
2.3. Data Analysis. Fireﬂy luciferase activities were nor-
malized with the corresponding Renilla luciferase reporter
activity as internal control. Fold induction was calculated by
taking the control DMSO (Sigma-Aldrich) as baseline.
3. Results
Transient transfection assays in human hepatoma HepG2
cells were done to compare L162-PPARα to V162-PPARα
transcriptional activity. In sum, two independent transients’
transfection assays were performed with similar results for
transcriptional activity. The V162-PPARα variant showed
similar basal transcriptional activity after treatment with
DMSO compared with L162-PPARα on the DR1x6-PPRE.
For positive control, the presence of the PPAR synthetic
ligand, ciproﬁbrate, showed enhanced transactivation activ-
ity in V162-PPARα compared with L162-PPARα (Figure 1).
Most importantly, the results from this functional study
demonstrate that increase in activity in the V162-PPARα
variant did not reach the same level of extent of transcrip-
tionalactivityastheL162-PPARαvariantinallreplicatesand
doses of omega-3 FAs.
Inmoredetails,theaddition of5and15μMEP Ar es ult ed
inanincreasedinactivitywithrespecttobasallevelofEPAof
1μM in L162-PPARα variant, yet only 15μME P Ar e s u l t e di n
a slight increase in transcriptional rate compared to DMSO
(Figure 1). In the same way, the addition of 5, 10, and 15μM
EPA resulted in an higher activity, with respect to basal
level in V162-PPARα variant (Figure 1). Nevertheless, tran-
scriptional activity by the L162-PPARα variant compared to
V162-PPARα variant was 9%, 11%, 4% and 6% consistently
g r e a t e rw i t h1 ,5 ,1 0 ,a n d1 5μMo fE P A( Figure 1) represent-
ing functional diﬀerences between the variants.
Similarly, the addition of DHA enhanced transcrip-
tional activity at most concentrations in both the L162-
PPARα and V162-PPARα variant compared to basal level
of DHA (Figure 1). However, only 10 or 15μM of DHAPPAR Research 3
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Figure 1: Transcriptional activity by L162-PPARα and V162-
PPARαinHepG2cellssupplementedwithEPA,DHA,andmixtures
of EPA:DHA. The DR1-PPRE-TKpGL3 reporter construct (100ng)
was cotransfected with the pRL-NULL plasmid (30ng) in HepG2
cells in presence of 10ng pSG5-hPPARα wild-type (black bars) or
mutated (white bars) and pSG5-mRXRα (10ng) plasmids. Cells
were subsequently treated or not with ciproﬁbrate (250μM) or
varying concentrations and mixtures of EPA and/or DHA for 24
hours. Values were normalized to internal Renilla luciferase activity
a sd e s c r i b e di nm a t e r i a l sa n dm e t h o d sa n de x p r e s s e da sf o l d -
induction relative to the control (TK-pGL3) set at 1. Values are
representative of 2 independent experiments realized in triplicates.
in the L162-PPARα increased activity compared to DMSO.
Likewise, the addition of 1, 5, 10, or 15μM of DHA increased
to a greater extent the transcriptional activity by the L162-
PPARα variant compared to the V162-PPARα variant (17%,
5%, 15%, and 3%; resp.) (Figure 1).
In addition, EPA:DHA mixtures tested showed a marked
increase in transcriptional activity that was higher with
respect to individual FA transcriptional activity or basal
activity (Figure 1). Again in the V162-PPARα variant, the
ratios of EPA:DHA increased the receptor activity but to a
lesser degree than in L162-PPARα (Figure 1). The disparities
in transcriptional activity between the L162-PPARα and
V162-PPARα variants were even more important: 24%,
28%, and 17% for 5:5, 5:15 and 15:5μM EPA:DHA ratios,
respectively. Overall, even if the individual FAs show a
smaller transcriptional activity by PPARα with a larger stan-
dard deviation, this transcriptional activity is consistently
lower in the V162-PPARα than L162-PPARα. Further, this
information is supported by the results of the mixtures of
EPA:DHA, where there is clearly an increased transcriptional
activity and this eﬀect is of lesser magnitude in V162-PPARα
than L162-PPARα.
4. Discussion
The present study represents the ﬁrst examination of the
variation in transcriptional activity after omega-3 FA activa-
tion in the L162V polymorphic variant. Overall, the use of
natural PPARα agonists, such as omega-3 FAs, may inﬂuence
the activation of PPARα at higher doses. Nevertheless, diﬀer-
encesexistintheratesoftranscriptionalactivitybytheV162-
PPARα and the L162-PPARα variant of the PPARα L162V
polymorphism. In addition, the additive eﬀects of EPA and
DHA mixtures on transcription rates may reveal supplemen-
tary beneﬁts compared to the individual omega-3 FAs.
The results clearly reveal that the V162-PPARα has lower
transcriptional activity than the L162-PPARα.P r e v i o u s
research has demonstrated the impact of PPARα on the
clearance of TG-rich lipoproteins in humans after treatment
with PPARα agonist, ﬁbrates [15]. The plasma TG lowering
eﬀect of ﬁbrates can be duplicated in animal studies [16]. In
contrast, plasma TGs are elevated in animals lacking PPARα
[17]. This data suggest that PPARα adjusts LPL-dependent
TG lypolysis by altering expression of pro- and antilipolytic
factors [18]. Thus, the current results demonstrate that
individuals carrying a V162-PPARα variant may potentially
have elevated TG levels due to lower transcription rate of
target genes, such as LPL. These in vitro results support
the numerous human studies in which the PPARα L162V
polymorphism exhibited associations with total cholesterol,
LDL-cholesterol, apo B, TG, and high-density lipoproteins
(HDL)-cholesterol [4–9]. In general, from the current and
previous human studies, the V162 allele appears to be
associated with a more harmful lipid proﬁle potentially due
to a lower transcription rate of target genes with PPREs.
The improve transactivation of both allelic variants
following an omega-3 FA activation reveals the importance
ofstratifyingindividualsaccordingtotheirdietaryfatintakes
including omega-3 FA to demonstrate the inﬂuence of
PPARα L162V polymorphism on lipid parameters and other
metabolic factors. Since the mutation is located in the DNA
binding domain, this single nucleotide polymorphism is
thought to have an impact on the receptor’s ability to bind
DNA [12]. While receptors coregulators (i.e., coactivators
and corepressors) generally interact with the ligand binding
domain of nuclear receptors [19], we cannot exclude that the
L162V amino acid substitution aﬀects the PPARα’s ability to
adequately separate from cytoplasmic corepressor, transit to
the nuclei and/or recruit coactivators, as it was demonstrated
for the V227A variant of this receptor [20]. To the best of
ourknowledgefunctionalstudieshaveneverbeenperformed
for the PPARα L162V mutation, and the mechanisms at the
basis of diﬀerential omega-3 FAs-dependent activation of the
wild-type and mutated receptors remain to be elucidated.
Yet, it appears that the V162-PPARα has the potential to
reach comparable transcription rates as L162-PPARα with
higher intakes of individual or mixtures of omega-3 FAs.
Therefore, the inﬂuence of the L162V polymorphic variant
may be more apparent in individuals who consume a lower
intake of omega-3 FAs. These results are in accordance with
previous human studies [10, 11, 21] which examined the
eﬀect of the PPARα L162V polymorphism in relation to diet.4 PPAR Research
These previous researchers determined that a high intake of
dietary PUFA can lower TG in carriers of the V162-PPARα
allele [10, 11] due to higher n-3 FA intakes that may lead
to increased activation of PPARα.F i n a l l y ,ar e c e n ts t u d yb y
Caron-Dorval et al. in 2008 [21] demonstrated that plasma
TG levels decreased similarly between a group of 28 young
men with or without the L162V polymorphism after an
intense omega-3 FA supplementation for 4 weeks. These
results conﬁrm that dietary modiﬁcations including higher
amounts of EPA and DHA, which activate PPARs to a greater
level, may be an eﬀective method in reducing metabolic risk
in those with high-risk allele, such as V162. However, this
point requires further investigation to ascertain a precise
nutritional recommendation.
An additional purpose of this study was to determine
whether EPA, DHA, and combinations of EPA:DHA have
diﬀerential roles in transcriptional activity. Most stud-
ies regarding the eﬀects of n-3 PUFA on blood lipids
were conducted with ﬁsh oils that contain a mixture of
EPA and DHA [22, 23]. Yet, a number of studies have
been conducted with EPA and DHA individually. In vitro
[24] and animal [25–28] studies suggest that EPA rather
than DHA may be a hypotriglyceridemic agent. However,
divergent ﬁndings have been reported in human studies
[29, 30]. Results from the current study with individual
FAs indicate that a higher dose of either EPA or DHA
can increase transcriptional rate of target genes. However,
our results demonstrated that DHA may have a slightly
higher transcriptional activity than EPA. A recent study by
Sanderson et al. in 2008 [31] showed that DHA behaved
as a highly potent inducer of PPARα dependent gene
expression compared to other FAs, although they did not
examine the eﬀects of EPA or mixtures of these FAs. On
the other hand, investigators who examined the eﬀects of
oleic acid, EPA, and DHA on intestinal gene expression
in mice identiﬁed 19, 46, and 41 genes, respectively, that
were activated with these fatty acids versus 74 genes with
the PPARα agonist [32]. In addition in the current study,
all tested concentrations of combination of EPA and DHA
induced slightly higher transcription rates than individual
FAs. However, it still remains unclear whether EPA and
DHA have similar TG lowering potential. Further studies are
neededtodeterminewhetherEPAandDHAincombination,
as they are found naturally in ﬁsh oils, have an additive
eﬀects on gene expression rates; hence, potentially reducing
TG concentrations to a greater extent than individual
FAs.
In conclusion, these results indicate that the V162-
PPARα variant has lower transcriptional activity than L162-
PPARα variant in response to omega-3 FAs; therefore,
clearly demonstrating that a nutrient-gene interaction exists
between PPARα L162V polymorphism and omega-3 FAs.
Furtherstudiesareneededtoconﬁrmwhetherthisdiﬀerence
in transcriptional activity by PPARα is translated into
diﬀerences in gene expression levels of physiological target
genes. Overall, the functional understanding of omega-3 FAs
in relation to PPARα L162V genotypes may allow more
targeted individualized dietary advice to maximising the
beneﬁt gained by the individual.
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